Anti-C5 (Eculizumab), Humanized Antibody

Anti-C5 (Eculizumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a recombinant humanized IgG2/4 kappa monoclonal antibody that inhibits the cleavage of C5 into C5a and C5b by C5 convertases. Inhibition of C5 cleavage prevents the generation of the terminal complement complex C5b-9. Both C5a and C5b-9 have proinflammatory and prothrombic properties and play a significant role in complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The original monoclonal antibody received FDA approval for the treatment of PNH and aHUS. This monoclonal antibody also received approval to treat adults suffering from general Myasthenia Gravis (gMG) but are anti-AChR antibody-positive.

Immunogen Sequence:Eculizumab

Target Alternative Name:C5D, C5a, C5b, ECLZB, CPAMD4, C5, Complement C5

Species Reactivities:Human

Tag Line:A humanized monoclonal antibody that targets complement protein C5 and prevents activation of the terminal complement complex C5b-9 which has a central role in disorders such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and Myasthenia Gravis (gMG)

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.